Every material Form 8-K MARAVAI LIFESCIENCES HOLDINGS, INC. has filed with the SEC since May 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Maravai LifeSciences reported second quarter 2026 revenue of $51.4 million, up 8.5% from the prior year, and a net loss of $21.6 million, compared with a net loss of $69.8 million in the second quarter of 2025. The company raised its full year 2026 Adjusted EBITDA guidance to $33 million to $35 million, from $30 million to $32 million, and reiterated its full year 2026 revenue guidance of $205 million to $215 million.
Q2 2026 revenue was $51.4 million, up 8.5%; TriLink rose 11.5% and Cygnus rose 2.8%.
Net loss narrowed to $21.6 million from $69.8 million a year earlier; net loss attributable to Maravai shareholders was $12.4 million.
Net loss per Class A common share was $(0.08), compared with $(0.27) in the second quarter of 2025.
Full year 2026 Adjusted EBITDA (non-GAAP) guidance raised to $33.0 million to $35.0 million; revenue guidance of $205.0 million to $215.0 million reiterated.
On June 2, 2026, Maravai entered a new credit agreement with a $150.0 million term loan and a $30.0 million revolving credit facility, both maturing June 2, 2032. Loan proceeds and about $98.5 million of cash on hand were used to repay in full the prior credit agreement, which was due October 2027. The company says this reduces its long-term debt principal from about $242.9 million to $150.0 million, though the new term loan carries a variable rate of SOFR plus 5.00%.
New $150.0 million term loan and $30.0 million revolving credit facility, both maturing June 2, 2032.
Prior credit agreement, due October 2027, was prepaid in full and terminated on June 2, 2026.
Company states long-term debt principal falls from about $242.9 million to $150.0 million.
Term loan bears interest at SOFR plus 5.00% per annum; revolver carries a 0.50% annual commitment fee on unused amounts.
Maravai LifeSciences reported first-quarter 2026 revenue of $65.8 million, up 40.5% from a year earlier, and a net loss of $6.4 million, compared with a $52.9 million loss in the prior-year quarter. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance, though the TriLink revenue jump includes $14.3 million of high-volume COVID-19 vaccine CleanCap orders.
Q1 2026 revenue was $65.8 million, up from $46.9 million; TriLink revenue rose 65.1% and Cygnus rose 1.4%
Net loss narrowed to $(6.4) million from $(52.9) million; Adjusted EBITDA was $20.3 million versus $(10.5) million
Full-year 2026 revenue guidance raised to $205.0 million to $215.0 million from $200.0 million to $210.0 million
Full-year 2026 Adjusted EBITDA guidance raised to $30.0 million to $32.0 million from $18.0 million to $20.0 million; free cash flow was $4.2 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MARAVAI LIFESCIENCES HOLDINGS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →